A quick look back at top stories.

Vanda Pharmaceuticals Inc. gained U.S. FDA approval for Bysanti (milsaperidone), cleared for use in acute bipolar I disorder and schizophrenia and ensuring continuation of the firm’s atypical antipsychotic franchise, with Fanapt (iloperidone) set to start losing patent protection in 2027. It also offered a rare straightforward regulatory win for Vanda, which has tussled with the FDA in recent years.

Total raised in public, private and other financings of biopharma companies, comparing 2019-2026.

Year-to-date money raised in public, private and other financings of biopharma companies.

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Acrotech, Astrazeneca, Breath Diagnostics, Daiichi, Dror Ortho Design, GE Healthcare, Hansa, Pilatus, Regeneron, Sibel, Skylinedx.

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Angiodynamics, Briacell, Briapro, Cassava, Catheter Precision, Devonian, Johnson & Johnson, Senseonics, Sequel.

Clinical updates for biopharma and med tech, including data readouts and publications: Avidity, Merck, Myriad Generics, Traws, Viiv, Yoltech.

Biopharma and med-tech companies raising money in public or private financings, including: 20/20 Biolabs, Altesa, Compass, Elumn8, Envoy, Eupraxia, Medical 21, Moleculin, Oncopeptides, Resverlogix, Sift, Starget, Ten63.

New hires and promotions in the biopharma and med-tech industries, including: Artiva, Ataibeckley, Fize, Integrated, Novabridge, Phio, Reacta.